JP2016503399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503399A5 JP2016503399A5 JP2015539782A JP2015539782A JP2016503399A5 JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5 JP 2015539782 A JP2015539782 A JP 2015539782A JP 2015539782 A JP2015539782 A JP 2015539782A JP 2016503399 A5 JP2016503399 A5 JP 2016503399A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- cetuximab
- administered
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718430P | 2012-10-25 | 2012-10-25 | |
| US61/718,430 | 2012-10-25 | ||
| PCT/US2013/066564 WO2014066606A2 (en) | 2012-10-25 | 2013-10-24 | Combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503399A JP2016503399A (ja) | 2016-02-04 |
| JP2016503399A5 true JP2016503399A5 (cg-RX-API-DMAC7.html) | 2016-12-08 |
Family
ID=50545472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539782A Pending JP2016503399A (ja) | 2012-10-25 | 2013-10-24 | 組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150273057A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2911673A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016503399A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150070393A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104812391A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013334599B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015009134A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2889530A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015005307A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015119218A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014066606A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181243B2 (en) * | 2013-12-03 | 2015-11-10 | Hangzhou Pushai Pharmaceutical Technology Co. Ltd. | Solvate form M of trametinib dimethyl sulfoxide and methods of making and using thereof |
| CA2933311A1 (en) * | 2013-12-12 | 2015-06-18 | Novartis Ag | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| WO2016029002A2 (en) * | 2014-08-22 | 2016-02-25 | Clovis Oncology, Inc. | Growth factor receptor inhibitors |
| JP6214790B2 (ja) * | 2014-09-16 | 2017-10-18 | イース チャーム リミテッド | 抗ｅｇｆｒ抗体および同抗体の使用法 |
| WO2017019279A1 (en) * | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| JP2019513767A (ja) * | 2016-04-15 | 2019-05-30 | イーライ リリー アンド カンパニー | マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法 |
| WO2017210538A1 (en) * | 2016-06-03 | 2017-12-07 | Giordano Caponigro | Pharmaceutical combinations |
| RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| KR102260995B1 (ko) * | 2018-11-28 | 2021-06-04 | 국립암센터 | Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| EP4259147A4 (en) * | 2020-12-11 | 2024-10-23 | Erasca, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| RS50569B (sr) * | 2004-06-11 | 2010-05-07 | Japan Tobacco Inc. | Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka |
| WO2008101840A1 (en) * | 2007-02-23 | 2008-08-28 | F. Hoffmann-La Roche Ag | Combination of erlotinib and mek-inhibitors for inhibiting proliferation of tumor cells |
| CN101998851A (zh) * | 2008-02-08 | 2011-03-30 | 帕纳德制药公司 | 吡铂和西妥昔单抗治疗结直肠癌的用途 |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| AU2010289794B2 (en) * | 2009-08-24 | 2014-10-02 | Genentech, Inc. | Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels |
| PL3560498T3 (pl) * | 2009-10-16 | 2022-12-12 | Novartis Ag | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
| WO2011133819A2 (en) * | 2010-04-21 | 2011-10-27 | Ventirx Pharmaceuticals, Inc. | Methods of enhancing antibody-dependent cellular cytotoxicity |
| FR2968557A1 (fr) * | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| CA2820709C (en) * | 2011-02-28 | 2016-02-16 | Sunshine Lake Pharma Co., Ltd. | Substituted quinoline compounds and methods of use |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| TWI601725B (zh) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| PT2897620T (pt) * | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
-
2013
- 2013-10-24 CN CN201380056222.9A patent/CN104812391A/zh active Pending
- 2013-10-24 JP JP2015539782A patent/JP2016503399A/ja active Pending
- 2013-10-24 KR KR1020157013212A patent/KR20150070393A/ko not_active Ceased
- 2013-10-24 BR BR112015009134A patent/BR112015009134A2/pt not_active IP Right Cessation
- 2013-10-24 US US14/437,231 patent/US20150273057A1/en not_active Abandoned
- 2013-10-24 MX MX2015005307A patent/MX2015005307A/es unknown
- 2013-10-24 RU RU2015119218A patent/RU2015119218A/ru not_active Application Discontinuation
- 2013-10-24 WO PCT/US2013/066564 patent/WO2014066606A2/en not_active Ceased
- 2013-10-24 CA CA2889530A patent/CA2889530A1/en not_active Abandoned
- 2013-10-24 EP EP13848440.7A patent/EP2911673A4/en not_active Withdrawn
- 2013-10-24 AU AU2013334599A patent/AU2013334599B2/en not_active Ceased